Our company has been awarded ‘AIMA – Dr. J S Juneja’ for Creativity and Innovation for Micro Small & Medium Enterprises, 2016 by Dr. J S Juneja, Past President of AIMA and Former Chairman.
Category: News
TEAM FENFURO is participating in Vitafoods Asia 2017. Please visit us at Booth No. E-29 at Sands Expo & Convention Centre at Marina Bay Sands in Singapore from 5-6 September, 2017
TEAM FENFURO is participating in Vitafoods Europe 2017. Please visit us at Booth No. J156 at Palexpo Geneva, Switzerland from 9 – 11 May 2017
We have exhibited in Vitafoods Asiaworld-Expo,Hong Kong on 1-2 September’ 2016 & we are pleased to inform you that our product GRECOBE is the winner as ‘Best Tasting Functional Beverage’
Poster Presentation on ‘Lowering of Blood Pressure in Diabetic Patients Receiving FENFURO ‘ by Dr.Manish Kumar Verma, Prof.Anuj Maheshwari & Prof. N.S.Verma.
Enlarged prostate gland is a common problem in the ageing males. It is also called Benign Prostatic Hyperplasia (BPH). The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. As the prostate gets bigger, it may squeeze or partly block the urethra. This often causes problems with urinating. The prevalence of histologically diagnosed prostatic hyperplasia increases from 8 percent in men aged 31 to 40, to 40 to 50 percent in men aged 51 to 60, to over 80 percent in men older than age 80.
Chemical Resources (CHERESO) has announced the acceptance of its patent (A novel process for extraction of Pygeum from indigenous resources) by USPTO (United States Patent & Trademarks Office), which extends the scope of phytotherapy in getting therapeutic relief from Benign Prostatic Hyperplasia (BPH). Pygeum is used as the main ingredient in PROSMAN, a first of its kind product to aid BPH treatment. PROSMAN has no side effects and is safe for consumption.
CHERESO is the proud owner of 29 international patents in the segment of blood glucose management, polycystic ovary syndrome (PCOS) management, prostate and men’s health etc. CHERESO is also having its own branded formulation for these applications.
Pygeum contains numerous beneficial bioactive constituents, including phytosterols, the most bioactive phytochemicals and beta-sitosterols, which exhibit anti-inflammatory action by inhibiting the production of prostaglandins in the prostate. Other Pygeum components include Ferulic acid esters, which reduce levels of prolactin and pentacyclic triterpenes by inhibiting an enzyme involved in inflammation and also help reduce edema. These bioactive components of Pygeum extract are believed to exert the most important therapeutic effect in the treatment of Benign Prostatic Hyperplasia (BPH). It helps in reduction of the volume of the prostate gland and also have considerable effects on urine retention and frequency, which are the major problems associated with BPH. PROSMAN will soon be launched in the market after completion of the ongoing clinical studies.
The news has come as a ray of hope for patients of BPH. PROSMAN will enable them to enjoy a hale and hearty life.
Categories
Patent granted to Pygeum
We have granted patent to our product Pygeum in U.S. under the title
‘IMPROVED PROCESS FOR PYGEUM EXTRACTION’.
We are glad to inform that our Company has been awarded OUTSTANDING CONTRIBUTION TO NATIONAL DEVELOPMENT
Poster Presentation on “CLINICAL EVALUATION OF FENFURO (FUROSTANOLIC SAPONINS) IN PATIENTS WITH TYPE-2 DIABETES” at 6th World Congress of Diabetes India held on 9th to 12th April at Hotel ITC Grand Chola Convention Centre Chennai.
